Skip to main content
NewslettersWatchlist

Regeneron Pharmaceuticals(REGN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low735.95
Day High757.55
Open:744.87
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Stock Target Advisor
Regeneron Pharmaceuticals: A Top Biotechnology Pick with 59.5% Upside Projection
Barchart
Stocks Settle Sharply Lower on the Outlook for Slower Fed Rate Cuts
GlobeNewswire
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
Motley Fool
2 Top Growth Stocks to Buy on the Dip
GlobeNewswire
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH
GlobeNewswire
Regeneron Announces Investor Conference Presentations
MarketBeat
3 Recession-Resistant Stocks: Low Beta, High Margins, Low Debt
Motley Fool
Is It Time to Buy October's Worst-Performing Nasdaq Stocks?
GlobeNewswire
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
GlobeNewswire
Regeneron Reports Third Quarter 2024 Financial and Operating Results
Motley Fool
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
GlobeNewswire
Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI
GlobeNewswire
Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular Edema
MarketBeat
These 3 Stocks Are Screaming Oversold: Seize the Opportunity
Motley Fool
Should You Buy the Dip on This Top Growth Stock?
Barchart
Stocks Settle Higher as Chinese Stimulus Boosts Economic Growth Prospects
Barchart
Stocks Slightly Higher as Chinese Stimulus Boosts Risk Sentiment in Asset Markets
Barchart
Stocks Climb as Chinese Stimulus Measures Boost Risk Sentiment
Newswire.ca
Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase
Barchart
Stock Index Futures Climb as China Stimulus Buoys Global Risk Appetite
Barchart
Stocks Settle Higher on the Scope for Further Fed Easing
Motley Fool
Prediction: These 2 Companies Will Split Their Stocks by 2027

Profile

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also developed an antibody cocktail for COVID-19, REGEN-COV. REGEN-COV is a cocktail of two monoclonal antibodies and was designed specifically to block the infectivity of SARS-CoV-2, the virus that causes COVID-19. Regeneron has a collaboration agreement with Roche for the same. While Regeneron has co-developed Eylea with Bayer's HealthCare unit, Praluent was co-developed with Sanofi. Regeneron collaborated with Bayer for the joint development and commercialization of co-formulated combinations of Eylea, rinucumab and nesvacumab for the treatment of ocular diseases or disorders outside the United States.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.